• Home
  • MK256 is a novel CDK8 inhibitor with potent antitumor activity in AML through downregulation of the STAT pathway.

MK256 is a novel CDK8 inhibitor with potent antitumor activity in AML through downregulation of the STAT pathway.

Author List
Lee JC, Liu S, Wang Y, Liang Y, Jablons DM
Publication
Oncotarget
Publication ID (Profile URL)
https://researcherprofiles.org/profile/366108067
Publication Year
2022
PubMed ID
36342456
Publication Title
Lee JC, Liu S, Wang Y, Liang Y, Jablons DM. MK256 is a novel CDK8 inhibitor with potent antitumor activity in AML through downregulation of the STAT pathway. Oncotarget. 2022 11 02; 13:1217-1236.